



COVID-19: KEEPING UP WITH A MOVING TARGET

July 22, 2020 UPDATE

Paul Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland



Postgraduate Institute
for Medicine



JOHNS HOPKINS
NURSING



CME Information

Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	Scientific Advisor: DiaSorin, Shionogi Inc. JNJ: Ownership equity

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials. These include hydroxychloroquine/chloroquine, hydroxychloroquine/chloroquine in combination with azithromycin, lopinavir plus ritonavir, tocilizumab, corticosteroids, and COVID-19 convalescent plasma.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.





CME Information

To attest for CME/CE/AAPA credit, please visit
COVID19.dkbmed.com





Learning Objectives

- Discuss data pertaining to use of tocilizumab in patients with COVID-19
- Describe data pertaining to the relative efficacy of cloth versus surgical masks to reduce transmission of SARS-CoV-2
- Describe potential effects of low vaccine coverage





Thank You

This activity is supported by an educational grant from Pfizer, Inc.
and in-kind support by DKBmed, LLC.

All activity content and materials have been developed solely by
the activity directors, planning committee members, and faculty
presenters, and are free of influence from Pfizer, Inc.

Please see **COVID19.DKBmed.com** for additional resources and
educational activities





Paul Auwaerter, MD, MBA, FIDSA
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland





To submit your own question, please email QA@dkbmed.com





Can you provide any information or study review, if any, on the use of cloth face coverings vs surgical masks?





How do we safely reopen colleges without capacity to test and with asymptomatic transmission even using all the best mitigation techniques?





I am a part-time school nurse in Western Pennsylvania. Our parents are going to be able to choose from three patterns for their children's return to school: full time classroom, mixed classroom and virtual, and all virtual. Dr. Auwaerter, you didn't sound optimistic for the former two selections. What is your advice for someone like me?





Could HVAC units play a significant role in the acceleration of COVID-19 cases seen this summer in the sunbelt states?





**What is the relationship between the BCG vaccine
and risk of COVID-19?**





What is the relationship between use of proton pump inhibitors and risk of COVID-19?





What have the studies of tocilizumab and other IL-6-targeted drugs shown? Considering toci is used to manage cytokine release syndrome, isn't there some plausibility that it "should" work for severe COVID illness?





Between background vaccine hesitancy and distrust of the rapid vaccine development program (and some myths about COVID), uptake of any approved COVID vaccine may be disappointingly low. What percent of the population needs to be vaccinated to prevent the virus from circulating forever?





Do we know anything about co-infection of SARS-CoV-2 and influenza? How does coinfection affect outcomes?





Can you comment on the trial of inhaled interferon beta?





To receive CME/CE/AAPA credit:

- Complete the evaluation on at COVID19.DKBmed.com
- Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

To access more resources related to COVID-19:

- Access our resource hub at COVID19.DKBmed.com

To ask your own question, email: QA@dkbmed.com

